CHICAGO - Gadopiclenol is emerging as an alternative gadolinium-based MRI contrast agent. To learn more about the product's potential, we spoke with Prof. Dr. Christiane Kuhl from the University Hospital Aachen in Germany at RSNA 2022.
Kuhl provides research update on gadolinium-based contrast agent
Dec 4, 2022
Latest in Market Analysis
Nick Screaton becomes new BIR president
October 1, 2024
RCR President responds to Darzi diagnosis
September 23, 2024
Blackford names Meenan to chief product officer role
June 27, 2024
Halliday: AI is no silver bullet
June 11, 2024